Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics

Marisa K. Joubert; Meghana Deshpande; Jane Yang; Helen Reynolds; Christine Bryson; Mark Fogg; Matthew P. Baker; Jonathan Herskovitz; Theresa J. Goletz; Lei Zhou; Michael Moxness; Gregory C. Flynn; Linda O. Narhi; Vibha Jawa

doi:10.1371/journal.pone.0159328

Loading metrics

Open Access

Peer-reviewed

Research Article

Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics

Marisa K. Joubert ,

* E-mail: mjoubert@amgen.com (MJ); vjawa01@amgen.com (VJ)

Affiliation Department of Attribute Sciences, Amgen Inc., Thousand Oaks, California, United States of America
⨯
Meghana Deshpande,

Current address: Eurofins Lancaster Laboratories PSS, Thousand Oaks, California, United States of America

Affiliation Department of Clinical Immunology, Amgen Inc., Thousand Oaks, California, United States of America
⨯
Jane Yang,

Affiliation Department of Attribute Sciences, Amgen Inc., Thousand Oaks, California, United States of America
⨯
Helen Reynolds,

Affiliation Antitope Limited, Babraham Research Campus, Cambridge, United Kingdom
⨯
Christine Bryson,

Current address: Department of Haematology, University of Cambridge, Cambridge, United Kingdom

Affiliation Antitope Limited, Babraham Research Campus, Cambridge, United Kingdom
⨯
Mark Fogg,

Affiliation Antitope Limited, Babraham Research Campus, Cambridge, United Kingdom
⨯
Matthew P. Baker,

Affiliation Antitope Limited, Babraham Research Campus, Cambridge, United Kingdom
⨯
Jonathan Herskovitz,

Affiliation Department of Clinical Immunology, Amgen Inc., Thousand Oaks, California, United States of America
⨯
Theresa J. Goletz,

Affiliation Department of Clinical Immunology, Amgen Inc., Seattle, Washington, United States of America
⨯
Lei Zhou,

Affiliation Department of Medical Sciences, Amgen Inc., Thousand Oaks, California, United States of America
⨯
Michael Moxness,

Affiliation Department of Clinical Immunology, Amgen Inc., Thousand Oaks, California, United States of America
⨯
Gregory C. Flynn,

Affiliation Department of Attribute Sciences, Amgen Inc., Thousand Oaks, California, United States of America
⨯
Linda O. Narhi,

Affiliation Department of Attribute Sciences, Amgen Inc., Thousand Oaks, California, United States of America
⨯
Vibha Jawa

* E-mail: mjoubert@amgen.com (MJ); vjawa01@amgen.com (VJ)

Affiliation Department of Clinical Immunology, Amgen Inc., Thousand Oaks, California, United States of America
⨯

Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics

Marisa K. Joubert,
Meghana Deshpande,
Jane Yang,
Helen Reynolds,
Christine Bryson,
Mark Fogg,
Matthew P. Baker,
Jonathan Herskovitz,
Theresa J. Goletz,
Lei Zhou

Published: August 5, 2016
https://doi.org/10.1371/journal.pone.0159328

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Antigens
Is the Subject Area "Antigens" applicable to this article?

Thanks for your feedback.
T cells
Is the Subject Area "T cells" applicable to this article?

Thanks for your feedback.
Immune response
Is the Subject Area "Immune response" applicable to this article?

Thanks for your feedback.
Cytokines
Is the Subject Area "Cytokines" applicable to this article?

Thanks for your feedback.
Medical risk factors
Is the Subject Area "Medical risk factors" applicable to this article?

Thanks for your feedback.
Synthetic biotherapeutics
Is the Subject Area "Synthetic biotherapeutics" applicable to this article?

Thanks for your feedback.
Glycation
Is the Subject Area "Glycation" applicable to this article?

Thanks for your feedback.
Enzyme-linked immunoassays
Is the Subject Area "Enzyme-linked immunoassays" applicable to this article?

Thanks for your feedback.